Myocardial Infarction Market

Myocardial Infarction Market Highlights

The global myocardial infarction market is expected to cross a market size of USD 4.0 Billion by the end of 2033. The market size was valued at USD 2.1 Billion in 2023 and is expected to expand at a CAGR of 7.2% between 2024-2033.

• Over the mid-term, the growing incidence of cardiovascular diseases worldwide is the primary factor anticipated to drive the global myocardial infarction market.
• High cost of treatment is a major factor to challenge the market growth.
• The North America myocardial infarction market is projected to dominate the global market.

Myocardial Infarction Market Outlook

When the blood flow to a part of the heart is blocked for a long enough time, the part of the heart muscle dies or is damaged. This situation is also commonly known as a heart attack, and in medical terms, known as myocardial infarction. The blockage of the heart is usually as a result of cholesterol, buildup of fat or other substances.

According to our experts at KD Market Insights, one of the major factors anticipated to drive the growth of the myocardial infarction market is the growing incidence of cardiovascular diseases worldwide, which according to the World Health Organization (WHO) takes away 17.9 million lives every year. Hence, with the steady rise in the incidence of cardiovascular diseases globally, which also includes myocardial infarction, the demand for better diagnostic tools, therapies, and preventive measures for the disorder is going to increase, which in turn, is expected to contribute to the market growth in the coming years. Apotex Inc., AstraZeneca, and Bayer AG are some of the significant parties in the global market for myocardial infarction.

                                                   Get More Insights on This Report - Request Free Sample PDF

Myocardial Infarction Market Drivers – Analyst’s Observation

According to the analysts at KD Market Insights, some key growth drivers for the global myocardial infarction market are:

• Increasing awareness for myocardial infarction: Owing to the increasing incidences of heart attack globally, individuals worldwide are more aware about the risk factors associated with the condition, which majorly includes hypertension, diabetes, and obesity among others. This, as a result, has raised the need among individuals for preventive healthcare measures, such as regular healthcare screenings, early intervention, and modifications in lifestyle, which is expected to contribute to the market growth in the coming years.
• Expanding development in diagnostic tools for myocardial infarction: Medical imaging technologies in the healthcare industry has shifted to a different level in the current era, and this is further advancing forward at a rapid pace. The increasing availability of CT scans, MRI, and echocardiography have helped in the early detection and accurate diagnosis of the condition. Such advancements have also helped healthcare providers to enhance their service offerings to treat the condition, which is expected to contribute to the market growth in the coming years.

Which Probable Factors Could Hamper the Growing Myocardial Infarction Market Trend?

As per our KD Market Insights analysis, some of the challenges expected to limit the global market growth of myocardial infarction are:

• High cost of treatment: The cost of treatment associated with myocardial infarction, such as coronary artery bypass grafting (CABG), percutaneous coronary interventions (PCI), and other advanced treatments and interventions are usually very expensive, thereby limiting the accessibility of treatment for patients in low- and middle-income nations.
• Concern for side effects: The treatment of myocardial infarction possesses significant side effects and complications, such as an increase in the risk of bleeding during surgical procedures, and other postoperative complications, which is projected to hamper the adoption of these treatments.

How is the Global Myocardial Infarction Market Segmented?

Our experts at KD Market Insights have segmented the global myocardial infarction market research report as:

What are the Probable Factors Influencing the North America Myocardial Infarction Market Forecast?

The North America myocardial infarction market is majorly driven by the increasing availability of cardiac surgeons in the region, especially in the United States, along with the presence of a state-of-the-art medical facilities that have cutting-edge diagnostic technologies. The cardiac patients in the region have greater accessibility to high standard medical care and have greater awareness for preventive diagnosis of the condition. Such factors are therefore expected to contribute to the market growth in the coming years.

As per our analysts at KD Market Insights, the following five players lead the North America myocardial infarction market growth:

• Pfizer Inc.
• Amgen Inc.
• Bristol-Myers Squibb
• Merck & Co., Inc.
• Johnson & Johnson

Which Key Players Top the Global Myocardial Infarction Market Share?

As per our analysts at KD Market Insights, the competitive landscape of global myocardial infarction market facilitates our readers in identifying their closest competitors. The manufacturers who are associated with myocardial infarction market are raising their focus on expanding their presence, as well as their market share. The market has also been witnessing an upward movement in the number of collaborations between research institutions and key players, aimed at introducing advanced technologies and innovation of new products. Here is a list of the key players who top the global myocardial infarction market share:

• Apotex Inc.
• AstraZeneca
• Bayer AG
• Boehringer-Ingelheim
• Bristol-Myers Squibb Company
• Daiichi Sankyo Co. Ltd.
• Mylan N.V.
• Novartis AG
• Par Pharmaceutical Companies Inc.
• Pfizer Inc.

What are the Recent Developments Observed in the Myocardial Infarction Market?

Over the years, the experts at KD Market Insights have been observing the recent developments associated with global myocardial infarction market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

For instance, BioCardia, Inc. stated that it has been conducting the 3rd phase of its trial for CardiAMP cell therapy.

Further, Recardio Inc. stated that it has completed the 2nd phase trial of dutogliptin, aimed at regenerating myocardial function post-myocardial infarction.

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global Myocardial Infarction Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Drug Class
      2. By Route of Administration
      3. By Distribution Channel
      4. By Region
5. Market Segmentation by Drug Class
   1. Antiplatelet Agents
   2. Glycoprotein IIb/IIIa Inhibitors
   3. Antithrombotic Agents
   4. Beta-adrenergic Blockers
   5. Vasodilators
   6. Angiotensin-converting Enzyme (ACE) Inhibitors
   7. Angiotensin-receptor Blockers
   8. Analgesics
6. Market Segmentation by Route of Administration
   1. Oral
   2. Injectable
7. Market Segmentation by Distribution Channel
   1. Hospital Pharmacies
   2. Retail Pharmacies
   3. Online Pharmacies
8. Regional Analysis
   1. North America
      1. United States
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      2. Canada
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      3. Mexico
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
   2. Europe
      1. United Kingdom
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      2. Germany
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      3. France
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      4. Italy
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      5. Spain
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      6. Rest of Europe
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
   3. Asia Pacific
      1. China
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      2. Japan
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      3. India
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      4. Australia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      5. South Korea
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      6. Rest of Asia Pacific
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
   4. Latin America
      1. Brazil
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      2. Argentina
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      3. Colombia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      4. Rest of Latin America
         1. Market Size and Forecast
         2. Key Trends and Developments
         3.               Market Analysis by Drug Class, Route of Administration, and Distribution Channel
   5. Middle East & Africa
      1. South Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      2. Saudi Arabia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      3. UAE
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
      4. Rest of Middle East & Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug Class, Route of Administration, and Distribution Channel
9. Competitive Landscape
   1. Market Share Analysis
   2. Company Profiles
      1. Apotex Inc.
      2. AstraZeneca
      3. Bayer AG
      4. Boehringer-Ingelheim
      5. Bristol-Myers Squibb Company
      6. Daiichi Sankyo Co. Ltd.
      7. Mylan N.V.
      8. Novartis AG
      9. Par Pharmaceutical Companies Inc.
      10. Pfizer Inc.
10. Strategic Recommendations
11. Appendix
    1. List of Tables
    2. List of Figures
12. References